Leif Helth Jensen: New Chairman of BoD in Valderm
Leif Helth Jensen, the former CEO of Glycom and Co-founder of Neurosearch, Zealand Pharma and Santaris Pharma, is taking the lead as BoD Chairman in one of SEED Capital’s promising portfolio companies: Valderm.
Valderm develops the patented and well-documented compound Valrubicin. Valrubicin is used as a medical therapy for psoriasis and other skin diseases, such as actinic keratosis, characterized by hyperproliferation. With Leif Helth Jensen as BoD, Valderm will benefit from his strong trade knowledge and experience in a usually very heavily regulated industry.


